Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects With a History of Atherosclerotic Disease: Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P - TIMI 50)

Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects With a History of Atherosclerotic Disease: Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P - TIMI 50)

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Sep 2018

At a glance

  • Drugs Vorapaxar (Primary)
  • Indications Atherosclerosis; Cardiovascular disorders; Thrombosis
  • Focus Registrational; Therapeutic Use
  • Acronyms TRA-2P; TRA2degP-TIMI50; TRA2P-TIMI 50
  • Sponsors Merck & Co; Merck Sharp & Dohme
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 29 Aug 2018 Results assessing the effect of vorapaxar on biomarkers of platelet activation and coagulation activity in patients with stable coronary artery disease, presented at the ESC Congress 2018: Annual Congress of the European Society of Cardiology.
    • 15 Nov 2017 Results presented at the 90th Annual Scientific Sessions of the American Heart Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top